18|3|Public
25|$|People with {{positive}} cultures for Streptococcus pyogenes {{should be treated}} with penicillin as long as allergy is not present. The use of antibiotics will not alter cardiac involvement {{in the development of}} rheumatic fever. Some suggest the use of <b>benzathine</b> <b>benzylpenicillin.</b>|$|E
5000|$|QJ51RC24 <b>Benzathine</b> <b>benzylpenicillin,</b> {{combinations}} {{with other}} antibacterials ...|$|E
50|$|Pain and {{inflammation}} at {{the injection}} site is also common for parenterally administered <b>benzathine</b> <b>benzylpenicillin,</b> benzylpenicillin, and, {{to a lesser}} extent, procaine benzylpenicillin.|$|E
5|$|X-ray {{diffraction}} {{was used}} for the identification of antibiotic drugs such as: eight β-lactam (ampicillin sodium, penicillin G procaine, cefalexin, ampicillin trihydrate, <b>benzathine</b> penicillin, <b>benzylpenicillin</b> sodium, cefotaxime sodium, Ceftriaxone sodium), three tetracycline (doxycycline hydrochloride, oxytetracycline dehydrate, tetracycline hydrochloride) and two macrolide (azithromycin, erythromycin estolate) antibiotic drugs. Each of these drugs has a unique XRD pattern that makes their identification possible.|$|R
40|$|Syphilis is an infective sexually {{transmitted}} disease, {{caused by an}} anaerobic filamentous spirochete, named Treponema Pallidum, which may be present in variable and different clinical forms. Over the last decade, this pathology has emerged in Western Europe with an unusual recrudescence, despite the well-known preventive measures, 1, 2, 3, 4 probably due to easy of travel and loosening of national boundaries. 5 We describe {{a case of a}} middle-age Caucasian woman with oral secondary syphilis, which clinically and immuno-histologically simulated a pemphigus vulgaris (PV). A 47 year-old woman was referred to our Oral Medicine Unit by her general practitioner for a desquamative gingivitis localized at the anterior lower teeth and for a bullous-erosive lesion localized at the right edge of the tongue. The Nikolsky’s sign was positive. Histology with haematoxylin/eosin revealed a suprabasal epithelial detachment with a prominent eosino-neutrophilic infiltrate, suggesting a possible PV. Direct immunofluorescence (DIF) showed positive for intercellular cement substance (ICS), with its classic “net-like” aspect. Indirect immunofluorescence using monkey oesophagus, and ELISA testing for Dsg 1 / 3 and BP 180 / 230 were negative. The diagnosis of PV was confirmed and the patient received 75 mg of prednisone daily. One week after commencing therapy, she developed rosy-circular papulosquamous lesions on the palms and soles, for which she was referred to a dermatologist, who suspected a diagnosis of secondary syphilis and, thus, recommended stopping the corticosteroids and performing the serological tests for syphilis. The venereal disease research laboratory (VDRL) test showed a titer of 1 : 1280, the treponema pallidum hemagglutinin assay (TPHA) showed strong positivity as did the IgG fluorescent treponemal antibody-absorption (FTA-abs) test. Histology from the skin biopsy revealed a suprabasal epithelial detachment with an abundant mixed inflammatory infiltrate in the underlying dermis, unlike the common histopathology of syphilis. 6 Thus, the immuno-histochemistry (anti-CD 38) on the oral biopsy specimen was performed and revealed the presence of Treponema. After the diagnosis of secondary syphilis, she received 1. 200. 000 U. I. of <b>benzylpenicillin</b> <b>benzathine</b> twice a week and, four weeks later, all lesions healed. Syphilis is also known as “the great imitator”, due to its ability to present clinically multiform muco-cutaneous aspects. In the oral cavity, it may occur in all three stages and the two most common features of secondary syphilis are represented by maculopapular lesions and mucous patches, which may coalesce and give snail-track ulcers. Although oral ulcerations in secondary syphilis are rare findings, they have been described and may show as oval ulcers covered by a white or gray pseudomembrane. Our patient only had tongue ulceration, with an erythematous-erosive lesion of the lower gum. Such clinical features, supported by the immuno-histological findings of a suprabasal acantholysis with a strong positive IgG autoantibody signal against the ICS, and a positive C 3 C accumulation, led us to make an initial diagnosis of PV. Although the histological and clinical characteristics of secondary syphilis are somewhat variable, simulating different diseases, such as oral hairy leukoplakia, cutaneous eczema, nonetheless, to our knowledge, an acantholytic lesion with a positive DIF has never previously been described as a pattern of secondary syphilis. PV is an autoimmune muco-cutaneous blistering disease (AMBD), which, commonly, enters into the differential diagnosis with other autoimmune bullous diseases and not with infectious diseases, except the Herpes virus family. Thus, this case focuses on the probability of a possible serious misdiagnosis and, then, on the need to consider the AMBDs in the differential diagnosis of secondary syphilis. The routine serologic tests for syphilis are mandatory in all cases in which, during the therapy, the disease shows any curious abnormality, which might lie outside an AMBD...|$|R
50|$|Benzathine is a diamine {{used as a}} {{component}} in some medications including benzathine phenoxymethylpenicillin and <b>benzathine</b> <b>benzylpenicillin.</b> It stabilises penicillin and prolongs its sojourn when injected into tissues.|$|E
50|$|People with {{positive}} cultures for Streptococcus pyogenes {{should be treated}} with penicillin as long as allergy is not present. The use of antibiotics will not alter cardiac involvement {{in the development of}} rheumatic fever. Some suggest the use of <b>benzathine</b> <b>benzylpenicillin.</b>|$|E
50|$|<b>Benzathine</b> <b>benzyl{{penicillin}},</b> {{also known}} as benzathine penicillin G, is an antibiotic useful {{for the treatment of}} a number of bacterial infections. Specifically it is to treat strep throat, diphtheria, syphilis, and yaws. It is also used to prevent rheumatic fever. It is given by injection into a muscle.|$|E
50|$|The {{treatment}} of choice is a single dose of <b>benzathine</b> <b>benzylpenicillin</b> given by intramuscular injection, or a five-day to one-week course of either oral penicillin or intramuscular procaine benzylpenicillin. Erythromycin or doxycycline may be given instead {{to people who are}} allergic to penicillin. E. rhusiopathiae is intrinsically resistant to vancomycin.|$|E
50|$|Benzyl{{penicillin}}, {{also known}} as penicillin G, is an antibiotic used to treat a number of bacterial infections. This includes pneumonia, strep throat, syphilis, necrotizing enterocolitis, diphtheria, gas gangrene, leptospirosis, cellulitis, and tetanus. It is not a first-line agent for pneumococcal meningitis. Benzylpenicillin is given by injection into a vein or muscle. Two long acting forms <b>benzathine</b> <b>benzylpenicillin</b> and procaine benzylpenicillin are available for use by injection into a muscle.|$|E
50|$|<b>Benzathine</b> <b>benzylpenicillin</b> was {{patented}} in 1950. It {{is on the}} World Health Organization's List of Essential Medicines, {{the most}} effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 0.27 to 1.71 USD for a course of treatment. In the United States the medication costs 50 to 100 USD for a dose as of 2015. In the United Kingdom it costs the NHS about 0.95 to 1.89 pounds a dose as of 2015.|$|E
5000|$|The term [...] "penicillin" [...] {{is often}} used generically to refer to {{benzylpenicillin}} (penicillin G, the original penicillin found in 1928), procaine benzylpenicillin (procaine penicillin), <b>benzathine</b> <b>benzylpenicillin</b> (benzathine penicillin), and phenoxymethylpenicillin (penicillin V). Procaine penicillin and benzathine penicillin have the same antibacterial activity as benzylpenicillin but act {{for a longer period}} of time. Phenoxymethylpenicillin is less active against gram-negative bacteria than benzylpenicillin. Benzylpenicillin, procaine penicillin and benzathine penicillin can be given by intravenous or intramuscular injections, but phenoxymethylpenicillin can be given by mouth because of its acidic stability.|$|E
40|$|BackgroundImpetigo affects {{more than}} 110 million {{children}} worldwide {{at any one}} time. The major burden of disease is in developing and tropical settings where topical antibiotics are impractical and lead to rapid emergence of antimicrobial resistance. Few trials of systemic antibiotics are available to guide management of extensive impetigo. As such, we aimed to compare short-course oral co-trimoxazole with standard treatment with intramuscular <b>benzathine</b> <b>benzylpenicillin</b> in children with impetigo in a highly endemic setting. MethodsIn this randomised, controlled, non-inferiority trial, Indigenous Australian children aged 3 months to 13 years with purulent or crusted non-bullous impetigo were randomly assigned (1 : 1 : 1) to receive <b>benzathine</b> <b>benzylpenicillin</b> (weight-banded injection), twice-daily co-trimoxazole for 3 days (4 mg/kg plus 20 mg/kg per dose), or once-daily co-trimoxazole for 5 days (8 mg/kg plus 40 mg/kg per dose). At every visit, participants were randomised in blocks of six and 12, stratified by disease severity. Randomisation was done by research nurses and codes were in sealed, sequentially numbered, opaque envelopes. Independent reviewers masked to treatment allocation compared digital images of sores from days 0 and 7. The primary outcome was treatment success at day 7 in a modified intention-to-treat analysis. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN 12609000858291. FindingsBetween Nov 26, 2009, and Nov 20, 2012, 508 patients {{were randomly assigned to}} receive <b>benzathine</b> <b>benzylpenicillin</b> (n= 165 [156 analysed]), twice-daily co-trimoxazole for 3 days (n= 175 [173 analysed]), or once-daily co-trimoxazole for 5 days (n= 168 [161 analysed]). Treatment was successful in 133 (85 %) children who received <b>benzathine</b> <b>benzylpenicillin</b> and 283 (85 %) who received pooled co-trimoxazole (absolute difference 0 · 5 %; 95 % CI − 6 · 2 to 7 · 3), showing non-inferiority of co-trimoxazole (10 % margin). Results for twice-daily co-trimoxazole for 3 days and once-daily co-trimoxazole for 5 days were similar. Adverse events occurred in 54 participants, 49 (90 %) of whom received <b>benzathine</b> <b>benzylpenicillin.</b> InterpretationShort-course co-trimoxazole is a non-inferior, alternative treatment to <b>benzathine</b> <b>benzylpenicillin</b> for impetigo; it is palatable, pain-free, practical, and easily administered...|$|E
40|$|Background: Impetigo aff ects {{more than}} 110 million {{children}} worldwide {{at any one}} time. The major burden of disease is in developing and tropical settings where topical antibiotics are impractical and lead to rapid emergence of antimicrobial resistance. Few trials of systemic antibiotics are available to guide management of extensive impetigo. As such, we aimed to compare short-course oral co-trimoxazole with standard treatment with intramuscular <b>benzathine</b> <b>benzylpenicillin</b> in children with impetigo in a highly endemic setting. Methods: In this randomised, controlled, non-inferiority trial, Indigenous Australian children aged 3 months to 13 years with purulent or crusted non-bullous impetigo were randomly assigned (1 : 1 : 1) to receive <b>benzathine</b> <b>benzylpenicillin</b> (weight-banded injection), twice-daily co-trimoxazole for 3 days (4 mg/kg plus 20 mg/kg per dose), or once-daily co-trimoxazole for 5 days (8 mg/kg plus 40 mg/kg per dose). At every visit, participants were randomised in blocks of six and 12, stratified by disease severity. Randomisation was done by research nurses and codes were in sealed, sequentially numbered, opaque envelopes. Independent reviewers masked to treatment allocation compared digital images of sores from days 0 and 7. The primary outcome was treatment success at day 7 in a modified intention-to-treat analysis. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN 12609000858291. Findings: Between Nov 26, 2009, and Nov 20, 2012, 508 patients {{were randomly assigned to}} receive <b>benzathine</b> <b>benzylpenicillin</b> (n= 165 [156 analysed]), twice-daily co-trimoxazole for 3 days (n= 175 [173 analysed]), or once-daily co-trimoxazole for 5 days (n= 168 [161 analysed]). Treatment was successful in 133 (85...|$|E
40|$|The {{program for}} the {{prevention}} of acute rheumatic fever (ARF) and recurrent attacks of the disease includes primary and secondary prevention.  The basis for the primary prevention of ARF are activities aimed at increasing the level of the body’s innate immunity and adaptive responses to adverse environmental conditions, as well as the timely diagnosis and adequate antimicrobial therapy of group A streptococcus throat infections, such as sore throat and pharyngitis. Secondary prevention aims to prevent recurrent attacks and disease progression in individuals who have experienced ARF and provides regular twenty-four-hour administration of long-acting penicillin (<b>benzathine</b> <b>benzylpenicillin)</b> </p...|$|E
40|$|This article {{reports the}} first {{documented}} treatment of venomous snakebite with a polyvalent snake antivenom from the South African Institute for Medical Research in endangered African wild dogs (Lycaon pictus). Three juvenile male animals (6. 5 months of age) showed clinical signs after being bitten by an unidentified venomous snake. The signs included loss of appetite, disorientation, impaired locomotion, excessive facial swelling, profuse salivation, reduced respiratory effort and an apparent depressed mental state. Intravenous treatment with isotonic Ringer lactate solution, hetastarch 6 % and dexamethazone, subcutaneous administration of procaine benzylpenicillin and <b>benzathine</b> <b>benzylpenicillin,</b> and ultimately intravenous {{administration of the}} polyvalent snake antivenom resulted in the complete recovery of all three wild dogs. </p...|$|E
40|$|Objective To {{explore the}} {{clinical}} characteristics and pathophysiological mechanism of syphilitic optic neuritis.   Methods The clinical signs and symptoms, laboratory tests, electrophysiological examinations, imaging features, treatment and prognosis of 12 cases with syphilitic optic neuritis admitted in our hospital from January 2014 to March 2016 were retrospectively analyzed.   Results The main clinical manifestation was vision loss in 12 patients (18 eyes), with acute or subacute onset, monocular attack or one after other. Degrees of visual loss differed among these patients. They also presented visual field defect and ocular fundus changes. Cerebrospinal fluid (CSF) examination showed increased {{white blood cell}} and protein. Rapid plasma reagin (RPR) assay and Treponema pallidum hemagglutination assay (TPHA) in serum were positive. RPR assay/toluidine red unheated serum test (TRUST) and TPHA in CSF were positive. Visual-evoked potential (VEP) showed prolonged latency and declined amplitude of P 100 wave. MRI revealed optic atrophy, abnormal signs in medial orbital part or overall length of optic nerve. The vision was improved after intravenous injection of aqueous penicillin and muscular injection of <b>benzathine</b> <b>benzylpenicillin.</b>   Conclusions Neurosyphilis is a rare cause of optic neuritis. Differential diagnosis should be paid attention on syphilitic optic neuritis from idiopathic optic neuritis and ischemic optic neuropathy. Serologic test and CSF examination will be helpful for a clear diagnosis. Besides, early diagnosis and standard therapy are essential for vision recovery.   DOI: 10. 3969 /j. issn. 1672 - 6731. 2016. 07. 007 </p...|$|E
40|$|SummaryBackgroundIn {{order to}} develop {{guidelines}} {{for the use of}} antimicrobial agents, it is necessary to obtain detailed information on the prevalence of infectious diseases and antibiotic usage. MethodsA retrospective study was conducted among outpatients with acute infections visiting the emergency department of the University Hospital of León, Nicaragua. ResultsOver the course of one month, 2027 patients visited the emergency department. Seven hundred and thirty-two patients (36. 1 %) had an infection, with a total of 799 acute infections. The majority of patients (55. 9 %) were children. Respiratory tract infections (43. 4 %), urogenital infections (29. 5 %), and diarrhea or gastroenteritis of presumed infectious origin (8. 8 %) were the most frequent infections. Among respiratory tract infections, the most frequent diagnoses were community-acquired pneumonia (CAP; 31. 4 %), acute tonsillitis (28. 2 %), and the common cold (17. 6 %). CAP was treated with procaine benzylpenicillin in 70. 6 % of cases, whereas 84. 0 % of patients with acute tonsillitis were treated with a single dosage of <b>benzathine</b> <b>benzylpenicillin</b> intramuscularly. Among urogenital infections, the most frequent diagnosis was acute uncomplicated urinary tract infection (24. 2 %). Approximately a quarter of patients with uncomplicated urinary tract infections did not receive treatment according to the local guidelines. Of the patients with acute diarrhea, 27. 1 % were treated with antibiotics, while only a minority had leukocytes in Wright stain of the feces. ConclusionsIn conclusion our study shows that the use of antimicrobial agents is not optimal. Antibiotics were prescribed too often and not according to the local guidelines. This will further exacerbate the resistance problem in Nicaragua...|$|E
40|$|Background: In {{order to}} develop {{guidelines}} {{for the use of}} antimicrobial agents, it is necessary to obtain detailed information on the prevalence of infectious diseases and antibiotic usage. Methods: A retrospective study was conducted among outpatients with acute infections visiting the emergency department of the University Hospital of Leon, Nicaragua. Results: Over the course of one month, 2027 patients visited the emergency department. Seven hundred and thirty-two patients (36. 1 %) had an infection, with a total of 799 acute infections. The majority of patients (55. 9 %) were children. Respiratory tract infections (43. 4 %), urogenital infections (29. 5 %), and diarrhea or gastroenteritis of presumed infectious origin (8. 8 %) were the most frequent infections. Among respiratory tract infections, the most frequent diagnoses were community-acquired pneumonia (CAP; 31. 4 %), acute tonsillitis (28. 2 %), and the common cold (17. 6 %). CAP was treated with procaine benzylpenicillin in 70. 6 % of cases, whereas 84. 0 % of patients with acute tonsillitis were treated with a single dosage of <b>benzathine</b> <b>benzylpenicillin</b> intramuscularly. Among urogenital infections, the most frequent diagnosis was acute uncomplicated urinary tract infection (24. 2 %). Approximately a quarter of patients with uncomplicated urinary tract infections did not receive treatment according to the local guidelines. Of the patients with acute diarrhea, 27. 1 % were treated with antibiotics, while only a minority had leukocytes in Wright stain of the feces. Conclusions: In conclusion our study shows that the use of antimicrobial agents is not optimal. Antibiotics were prescribed too often and not according to the local guidelines. This will further exacerbate the resistance problem in Nicaragua. Crown Copyright (C) 2008 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. All rights reserved...|$|E
40|$|Every year, through mass drug {{administration}} (MDA), {{hundreds of millions}} of the world’s poorest people receive a single annual dose of one or more drugs to eliminate certain parasitic worm or bacterial infections. Some of these infections, mostly prevalent in tropical areas, have traditionally been neglected from the public health and research point of view. These conditions, collectively known as the neglected tropical diseases (NTDs), still cause, at the cusp of the second decade of the 21 st century, a significant amount of morbidity and mortality. The existing control measures for NTD have an enormous potential, although there are still some challenges that require further investigation. For some diseases, alternative strategies may be needed, including longer duration of MDA programmes or modified drug regimens. For other diseases, such as yaws, the work must start almost from scratch, since little has been achieved in terms of control of this disease in the past 50 years. Although eight NTDs affect the region, two diseases pose a major public health problem in the South Pacific Islands, namely yaws and lymphatic filariasis and are the basis for his thesis. These two infections were selected for a number of reasons. First, they affect the South Pacific region disproportionately. Secondly, little research has been conducted in the past years. And third, but more importantly, several epidemiological, technological and historical factors make these two diseases amenable to elimination. Safe and effective tools and interventions to achieve these targets are available and concerted efforts to scale them up are likely to lead to success. Yaws {{is one of the most}} neglected of the NTDs. Yaws was one of the first diseases to be targeted for eradication on a global scale, efforts which almost led to the disease disappearance as a result of a massive treatment program started in the 1950 s. After the successful eradication campaigns the primary health care systems were supposed to give the last push towards eradication of yaws. However a combination of various factors including poor political commitment and limited funding resulted in a progressive abandonment of efforts and the resurgence of the disease. Every new case of yaws was the disappointing confirmation that the public health world had missed a great opportunity. Today yaws has resurged in many tropical areas and presents new challenges including its unknown epidemiological situation, the attenuated clinical forms of the disease, a poor awareness and knowledge among health care workers, the lack of knowledge about the effectiveness of classic treatment with penicillin and, an obvious need for research into simplified administration schemes or new antibiotic treatments, particularly oral ones. There is an enormous knowledge gap regarding current reliable epidemiological information about the disease. Certainly we know little about the burden in the three Melanesian countries where the disease is highly endemic, Papua New Guinea, Solomon Islands and, Vanuatu. In Solomon Islands and Vanuatu there are indications that Yaws is widespread and prevalent, but we know that the diagnosis is unreliable. This takes us to the next point, what does a diagnosis of yaws mean? Overall the natural history of the disease in this era, where it is often subject to inadequate antibiotic pressure, is very unclear. Some authors have suggested that yaws appears to be attenuated in both Solomon Islands and Vanuatu. They state that bone involvement in yaws is now rare and implies that yaws is a mild disease not requiring efforts for elimination. However, the first paper of this thesis describes the epidemiology of yaws in Lihir Island (Papua New Guinea, PNG) and shows a high rate of classical primary ulcers (almost 60 %) and significant bone and periosteal involvement (more than 15 %), suggesting that “attenuation” is not an important issue. When we look at the diagnostic criteria for yaws, signs and symptoms alone are still used often in many areas to diagnose the disease. This reliance on clinical findings was the result of the difficulty of performing serological tests in remote areas. Today, available rapid serological tests are simple, rapid, inexpensive and useful for guiding confirmation of cases, making them adequate tools for the diagnosis and monitoring of the disease. The clinical diagnosis of yaws is complicated because its clinical manifestations may be unspecific. Thus, it is possible that a significant proportion of yaws cases may in fact have been falsely diagnosed. We show, in the first article, that in our experience only 60 % of the cases with a clinical suspicion of yaws were finally confirmed by serologic tests. Therefore, a proper diagnosis of yaws requires the interpretation of clinical findings with reference to laboratory results and the epidemiologic history of the patient. Serological testing in yaws is not only important for diagnostic accuracy, but also is very helpful in defining the disease’s evolution and eventual cure after treatment. Rapid plasma regain (RPR) titres should decline within 6 - 12 months, becoming negative in less than 2 years. The second article of this thesis combines a clinical and serological approach to assess the response after treatment with <b>benzathine</b> <b>benzylpenicillin,</b> and it identifies an overall 20 % treatment failure. This could be related to resistance to the antimicrobial drug used or to re-infection caused. The distinction between re-infection and true resistance to antibiotic treatment is difficult to make but these failures are worrisome. This article also proposes a multivariate model performed to identify independent determinants of failure that affected the outcome after treatment. The risk for reinfection caused by repeated contact with infected children seems to be a pivotal predictor of failure. Low baseline titters (< 1 : 32) of RPR are also an important and independent predictor of failure, possibly as a result of the greater difficulty in resolving chronic infections which are usually accompanied by low titters. With yaws re-emerging, the development of new strategies against this infection aimed at simplifying its treatment and potentially re-focussing strategies towards its eradication seems essential. Injectable penicillin is still effective but management with an oral drug that can be easily administered on a large scale should be the preferred method for treatment. To date, there had been no studies that directly compared the efficacy of penicillin with any of the potentially alternative agents shown to work in the treatment of the non-venereal treponematoses. The fourth paper in this thesis has shown that a single-dose of oral azithromycin is non-inferior to <b>benzathine</b> <b>benzylpenicillin</b> for the treatment of yaws in children in PNG. In an open-label randomised trial, at 6 -month follow-up, 96 % of patients treated with azithromycin were cured, as were 93 % in the <b>benzathine</b> <b>benzylpenicillin</b> group. The prospects of eliminating and eventually eradicating yaws may now be enhanced by the use of a single-dose of oral azithromycin in mass {{drug administration}} campaigns. Community based mass administration of azithromycin has been widely used in many locations for the control of trachoma, which, like yaws, is a disease of poor rural communities in developing countries, and has been used in a more limited way to control granuloma inguinale and outbreaks of venereal syphilis. Elimination of yaws and lymphatic filariasis in the South-Pacific Islands is now considered biologically feasible and programmatically attainable. The Global Programme to Eliminate Lymphatic Filariasis (GPELF) has expanded quickly to reach the target of elimination by 2020. On the other hand the strategy to eliminate yaws is again at the centre of discussions and given that infected humans are the only source of disease, its eradication could be achieved within a very relatively short time. The fifth article of the thesis comprehensively reviews antimicrobial treatments and elimination strategies against yaws. In order to control yaws and push it towards elimination, we propose to move away from penicillin to azithromycin and use mass treatment campaigns of the entire population in endemic communities irrespective of the prevalence. Also, to make sure all cases are tracked down and treated, strict follow-up measures and selective mass treatment will be required until zero case prevalence is reached. Importantly, we suggest testing the principle of interrupting transmission in pilot implementation studies, including prevalence surveys to assess the impact of the intervention and macrolide resistance monitoring which in our opinion will be essential evaluation tools to guide us towards a sustainable elimination. Lymphatic filariasis (LF), caused by the mosquito-borne nematode Wuchereria Bancrofti, is a major public-health problem in the Melanesian countries. Annual MDA over five years is currently the WHO’s recommended strategy to eliminate lymphatic filariasis. This approach aims to suppress microfilaraemia in infected individuals and bring the infection below a threshold that leads to interruption of transmission. However theoretical work and clinical field experience has highlighted how the ecological diversity between different endemic regions can result in elimination thresholds that vary between local communities. This means that the duration required might be different for different areas. Other variables have also been previously identified as potentially having an influence on the outcome of the program, including baseline prevalence of infection, vector density or the treatment coverage. The last article of this thesis provides data about the impact of a five-year filariasis control program in Papua New Guinea. The findings reported support this strategy for areas with low-to-moderate rates of transmission in regions where anopheline mosquitoes transmit this infectious disease. Additional measures or longer periods of treatment may be necessary in areas with a high rate of transmission. The experience acquired on Lihir Island in MDA programs during the campaigns for the elimination of filariasis, will be very valuable when implementing a pilot strategy for yaws control. Also, in the near future it might be important to link yaws mass treatment with other mass programmes to increase efficiency. The plan for elimination of lymphatic filariasis in PNG was approved as a pilot project in 2005 but the program still needs to be extended to the total of 20 provinces in the country where filariasis is endemic. In this context, an integrated approach to NTD control could represent an important global public health solution in PNG and other South Pacific Islands. Little has been achieved in the past decade in NTDs. We are now in a good position to translate into policies the results of our research projects. A new elimination policy for yaws around the azithromycin pillar has been sketched a WHO consultation meeting held in Morges, Switzerland last March. In the intentions of the organization, a last global mass campaign to tackle yaws should permit to reach zero cases in 2017, and the subsequent certification of worldwide interruption of transmission by 2020. Cada año, a través de la administración masiva de medicamentos (MDA), cientos de millones de personas, las más pobres del mundo, reciben una dosis única de uno o más medicamentos para eliminar ciertas infecciones, parasitarias o bacterianas. Algunas de estas infecciones, frecuentes sobre todo en las zonas tropicales, han sido tradicionalmente desatendidas desde el punto de vista de salud pública e investigación. Estas enfermedades, conocidas comúnmente como las enfermedades tropicales desatendidas (ETD), aún causan, en el inicio de la segunda década del siglo 21, una cantidad significativa de morbilidad y mortalidad. Las medidas de control actuales para ETDs tienen un enorme potencial, pero todavía existen algunas cuestiones que requieren investigación. Para algunas de estas infecciones, son necesarias estrategias alternativas, incluyendo una mayor duración de los programas de MDA o regímenes modificados de medicamentos. Para otras enfermedades, como la enfermedad de pián, el trabajo debe comenzar casi desde cero, ya que poco se ha logrado, en términos de control de esta enfermedad, en los últimos 50 años. Aunque ocho ETDs afectan a la región, dos enfermedades constituyen un problema importante de salud pública en las Islas del Pacífico Sur, a saber: el pián y la filariasis linfática y son la base de esta tesis. Estas dos infecciones fueron elegidas por muchas razones. En primer lugar, afectan a la región del Pacífico Sur de forma desproporcionada. En segundo lugar, pocas investigaciones se han llevado a cabo en los últimos años. Y en tercer lugar, pero lo más importante, varios factores epidemiológicos, tecnológicos e históricos hacen que estas dos enfermedades sean susceptibles de eliminación. Existen armas terapéuticas seguras y eficaces para lograr este objetivo, y esfuerzos coordinados para ejecutar los programas de control pueden conducir al éxito. El pián es una de las más olvidadas de las ETDs. Ésta fue una de las primeras enfermedades en ser objetivo de erradicación a escala global. Los esfuerzos de un programa de tratamiento masivo, que se inició en la década de 1950, casi llevaron a la desaparición de la enfermedad. Después de las exitosas campañas de erradicación, los sistemas de salud de atención primaria debían dar el último empujón hacia la erradicación del pián. Sin embargo, una combinación de varios factores, incluyendo un pobre compromiso político y una financiación limitada, dieron como resultado el abandono progresivo de los esfuerzos y el resurgimiento de la enfermedad. Cada nuevo caso de pián era la decepcionante confirmación de que el mundo de la salud pública había perdido una gran oportunidad. Hoy la enfermedad de pián ha resurgido en muchas áreas tropicales con nuevos desafíos: una situación epidemiológica desconocida, formas clínicas atípicas o atenuadas, poco conocimiento de la enfermedad entre el personal sanitario, la falta de datos acerca de la eficacia del tratamiento clásico con penicilina inyectable y la necesidad de desarrollar esquemas terapéuticos simplificados o investigar en nuevos tratamientos antibióticos, en especial de administración oral. Actualmente hay una enorme brecha de conocimiento entorno a la información epidemiológica fiable sobre la enfermedad. Ciertamente, sabemos poco acerca de la incidencia en los tres países melanesios, donde la enfermedad es altamente endémica, Papúa Nueva Guinea (PNG), Islas Salomón y Vanuatu. En las Islas Salomón y Vanuatu, las cifras de incidencia son muy altas lo que demuestra que el pián es una enfermedad frecuente y ampliamente extendida, pero sabemos que el diagnóstico no es muy fiable. Esto nos lleva al siguiente punto: ¿Cuáles son los criterios diagnósticos del pián? En general, la historia natural de la enfermedad en la época actual, donde la bacteria es objeto de presión antibiótica inadecuada, no es muy clara. Algunos autores han escrito que el pián parece presentar manifestaciones “atenuadas” en las Islas Salomón y Vanuatu. Afirman que la afectación ósea en el pián es poco frecuente, lo que implica que el pián es una enfermedad leve que no requeriría esfuerzos para su eliminación. Sin embargo, el primer trabajo de esta tesis describe la epidemiología del pián en la Isla de Lihir (Papúa Nueva Guinea) y muestra una alta tasa de úlceras primarias clásicas (casi el 60 % de casos) y una afectación significativa del hueso y periostio (más del 15 %) que sugiere que la "atenuación" no es un tema importante. Cuando nos fijamos en los criterios diagnósticos, únicamente signos y síntomas todavía se utilizan en muchas áreas para el diagnóstico de la enfermedad. Esta confianza en los hallazgos clínicos fue el resultado de la dificultad de realizar pruebas serológicas en las zonas remotas. Hoy en día, las pruebas serológicas rápidas son simples, rápidas, económicas y útiles para orientar la confirmación de los casos. El diagnóstico clínico del pián es complicado debido a que sus manifestaciones pueden ser inespecíficas. Así, es posible, que una proporción significativa de los casos de pián puedan haber sido falsamente diagnosticados. En el primer artículo, presentamos que, en nuestra experiencia, sólo el 60 % de los casos con sospecha clínica de pián fueron finalmente confirmados por pruebas serológicas. Por lo tanto, un diagnóstico adecuado del pián requiere la interpretación de los hallazgos clínicos con referencia a los resultados de laboratorio y la historia epidemiológica de los pacientes. Las pruebas serológicas en el pián no sólo son importantes para el diagnóstico de la enfermedad, también son muy útiles en la definición de curación después del tratamiento. En la prueba de la Reagina plasmática rápida (RPR) los títulos deben descender a los 6 - 12 meses, llegando a ser negativa en menos de 2 años. El segundo artículo de esta tesis combina un enfoque clínico / serológico para evaluar la respuesta a bencilpenicilina benzatina, e identifica una tasa de fracaso terapéutico del 20 % a los 12 meses del tratamiento. Esto podría estar relacionado con resistencia al fármaco antimicrobiano, o bien indicar una re-infección por re-exposición. La distinción entre la re-infección y la resistencia verdadera al tratamiento es difícil, pero estos fracasos terapéuticos son preocupantes. En este artículo se describe un modelo multivariante realizado para identificar los factores determinantes del fracaso terapéutico. El riesgo de re-infección causado por el contacto repetido con otros niños infectados parece ser un predictor fundamental de fracaso. También es un factor de riesgo, los títulos basales bajos (< 1 : 32) de RPR. Este último factor podría estar relacionado con la mayor dificultad para resolver infecciones crónicas (en estadio secundario), habitualmente acompañadas de títulos bajos. Con la enfermedad de pián re-emergiendo, el desarrollo de nuevas estrategias contra la infección para hacer más fácil los esfuerzos de erradicación es esencial. La penicilina inyectable sigue siendo eficaz, pero el tratamiento con un fármaco por vía oral que pueda ser fácilmente administrado a gran escala es el método preferido para el tratamiento, prevención y finalmente eliminación en todas las regiones endémicas del mundo. Hasta la fecha, no ha habido estudios que comparen directamente la eficacia de la penicilina con cualquiera de los agentes alternativos en el tratamiento de las treponematosis no venéreas. El cuarto artículo de esta tesis ha demostrado que una dosis única de azitromicina por vía oral no es inferior a la bencilpenicilina benzatina intramuscular, para el tratamiento del pián en niños en Papúa Nueva Guinea. En un ensayo abierto, aleatorio, el 96 % de los pacientes tratados con azitromicina estaban curados a los 6 meses de seguimiento, al igual que el 93 % en el grupo de bencilpenicilina benzatina. Las perspectivas de finalmente erradicar el pián son ahora mayores, mediante el uso de una dosis única de azitromicina oral en campañas masivas de tratamiento. El tratamiento masivo con azitromicina ha sido ampliamente utilizado para el control del tracoma, que, al igual que el pián es una enfermedad de comunidades rurales pobres de países en desarrollo. También se ha utilizado de una manera más limitada para controlar el granuloma inguinal y brotes de sífilis venérea. En general, el uso de azitromicina ha demostrado ser seguro, y de hecho ha habido beneficios inesperados de salud en algunos programas. La eliminación del pián y la filariasis linfática en las Islas del Pacífico Sur se considera ahora biológicamente factible y operacionalmente alcanzable. El Programa Global para Eliminar la Filariasis Linfática (GPELF) se ha expandido rápidamente para alcanzar la meta de eliminación en el año 2020. Por otro lado la estrategia para eliminar el pián es nuevamente centro de atención. Además, dado que los seres humanos infectados son la única fuente de la enfermedad, su eliminación podría lograrse en un plazo relativamente corto. El quinto artículo de la tesis revisa de forma integral el tratamiento con antimicrobianos y las estrategias de eliminación contra el pián. Con el fin de controlar el pián hasta la erradicación, se propone pasar de la penicilina a la azitromicina, y el uso de campañas de tratamiento masivo de toda la población en todas las comunidades endémicas. Además, para asegurar que todos los casos son encontrados y tratados, serán necesarias medidas estrictas de seguimiento y tratamiento masivo selectivo hasta llegar al objetivo de cero casos clínicos. Es importante destacar que el principio de interrupción de la transmisión se debe probar en estudios piloto, incluyendo estudios de prevalencia, para monitorizar el impacto de la intervención, y también la valoración de resistencia a macrolidos, que en nuestra opinión, serán herramientas fundamentales que nos guíen en el camino hacia una eliminación sostenible La filariasis linfática (FL), causada por el nematodo Wuchereria bancrofti, es otro de los grandes problemas de salud pública en los países de la Melanesia. Un curso de MDA anual, durante cinco años, es la estrategia que la OMS recomienda para eliminar la FL. Este enfoque tiene como objetivo suprimir la microfilaremia en los individuos infectados y disminuir los niveles de infección por debajo de un umbral que conduzca a la interrupción de la transmisión. Sin embargo, trabajo teórico y experiencia práctica clínica han puesto de relieve cómo la diversidad ecológica, entre diferentes...|$|E

